https://www.taxtmi.com/news?id=45559 Zydus will acquire two U.S. biologics CMC facilities from Agenus, including an upfront payment and contingent revenue linked consideration, becoming the exclusive contract manufacturer for two identified Phase 3 immuno oncology products and obtaining a first right of negotiation for future Agenus pipeline products; the acquired facilities and team will operate as an independent CDMO within Zydus, providing end to end biologics development and manufacturing capabilities and enabling workforce expansion and strategic presence in a major biotechnology hub. en-us Tue, 03 Jun 2025 17:46:05 +0530 Tue, 03 Jun 2025 17:46:05 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=45559 Zydus will acquire two U.S. biologics CMC facilities from Agenus, including an upfront payment and contingent revenue linked consideration, becoming the exclusive contract manufacturer for two identified Phase 3 immuno oncology products and obtaining a first right of negotiation for future Agenus pipeline products; the acquired facilities and team will operate as an independent CDMO within Zydus, providing end to end biologics development and manufacturing capabilities and enabling workforce expansion and strategic presence in a major biotechnology hub. News - Tue, 03 Jun 2025 17:46:05 +0530 https://www.taxtmi.com/news?id=45559